Merck KGaA Deal History & Licensing Activity
Merck KGaA is a large pharma headquartered in Germany. Over the past three years, Merck KGaA has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (2 deals). The company currently has 49 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
49
Top Modality
Antibodies
Focus Area
Solid Tumors
Merck KGaA Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Merck KGaA in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| tulisokibart (MK-7240) | Merck | Antibodies | Phase 2 | acquisition | Apr 2026 |
| Ogsiveo (nirogacestat) | SpringWorks Therapeutics | Small Molecules | Approved | acquisition | Apr 2025 |
Merck KGaA Pipeline Focus
Therapeutic areas and modalities where Merck KGaA is most active based on deal history and clinical trial data.
Therapeutic Areas
Merck KGaA Strategic Signals
Key indicators of Merck KGaA's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Merck KGaA Clinical Pipeline
Merck KGaA has 49 active clinical trials across 5 development phases.
1
Not Applicable
4
Unknown
22
Phase 1
15
Phase 2
7
Phase 3
See How Your Asset Matches Merck KGaA's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Merck KGaA Licensing & Deal Activity
Merck KGaA is a large pharma company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Merck KGaA ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Merck KGaA include Solid Tumors (22 deals and trials), CNS Disorders (4 deals and trials), Autoimmune (3 deals and trials), and Hematological Malignancies (3 deals and trials). In terms of modality, Merck KGaA has shown particular interest in antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Merck KGaA and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Merck KGaA's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.